Mark Sliwkowski
50Patents
25h-index
41Co-inventors
88Inventor score
Filing activity: Mar 25, 1997 → Oct 25, 2018
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6573043B1 | Tissue analysis and kits therefor | Physics | 181 | Expired |
| US6949245B1 | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies | Emerging Cross-Sectional Technologies | 161 | Expired |
| US7745394B2 | Monomethylvaline compounds capable of conjugation to ligands | Emerging Cross-Sectional Technologies | 149 | Active |
| US7097840B2 | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates | Chemistry; Metallurgy | 149 | Expired |
| US5968511A | ErbB3 antibodies | Physics | 148 | Expired |
| US7964566B2 | Monomethylvaline compounds capable of conjugation to ligands | Emerging Cross-Sectional Technologies | 140 | Active |
| US7994135B2 | Monomethylvaline compounds capable of conjugation to ligands | Emerging Cross-Sectional Technologies | 124 | Active |
| US7964567B2 | Monomethylvaline compounds capable of conjugation to ligands | Emerging Cross-Sectional Technologies | 93 | Active |
| US7485302B2 | Treatment with anti-ErbB2 antibodies and chemotherapeutic agents | Emerging Cross-Sectional Technologies | 75 | Expired |
| US8142784B2 | Antibody-drug conjugates and methods | Chemistry; Metallurgy | 69 | Active |
| US7575748B1 | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates | Chemistry; Metallurgy | 69 | Active |
| US7674589B2 | Methods for tissue analysis | Physics | 61 | Active |
| US7862817B2 | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies | Emerging Cross-Sectional Technologies | 60 | Active |
| US7041292B1 | Treating prostate cancer with anti-ErbB2 antibodies | Emerging Cross-Sectional Technologies | 53 | Expired |
| US7537931B2 | Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodies | Emerging Cross-Sectional Technologies | 49 | Active |
| US6696290B2 | ErbB2 and ErbB4 Chimeric Heteromultimeric Adhesins | Chemistry; Metallurgy | 42 | Expired |
| US6096873A | Gamma-heregulin | Emerging Cross-Sectional Technologies | 41 | Expired |
| US7501122B2 | Treatment with anti-ErbB2 antibody combinations | Emerging Cross-Sectional Technologies | 40 | Expired |
| US8663643B2 | Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use | Physics | 40 | Active |
| US7498030B2 | Treatment with anti-ErbB2 antibodies and anti-hormonal compounds | Emerging Cross-Sectional Technologies | 36 | Expired |
| US7618631B2 | Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs | Emerging Cross-Sectional Technologies | 35 | Active |
| US8163287B2 | Combination therapy of her expressing tumors | Chemistry; Metallurgy | 32 | Active |
| US7285649B2 | Isolated nucleic acids, vectors and host cells encoding ErbB3 antibodies | Physics | 31 | Expired |
| US6905830B2 | Tissue analysis and kits therefor | Physics | 25 | Expired |
| US6387638B1 | Heregulin variants | Physics | 25 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.